- Home
- OCG vs BIVI Comparison
OCG vs BIVI Comparison
Compare OCG & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCG
- BIVI
- Stock Information
- Founded
- OCG 2018
- BIVI 2013
- Country
- OCG Hong Kong
- BIVI United States
- Employees
- OCG N/A
- BIVI N/A
- Industry
- OCG Other Consumer Services
- BIVI Biotechnology: Pharmaceutical Preparations
- Sector
- OCG Consumer Discretionary
- BIVI Health Care
- Exchange
- OCG Nasdaq
- BIVI Nasdaq
- Market Cap
- OCG 21.0M
- BIVI 18.8M
- IPO Year
- OCG 2020
- BIVI N/A
- Fundamental
- Price
- OCG $3.39
- BIVI $0.95
- Analyst Decision
- OCG
- BIVI Strong Buy
- Analyst Count
- OCG 0
- BIVI 1
- Target Price
- OCG N/A
- BIVI $30.00
- AVG Volume (30 Days)
- OCG 160.9K
- BIVI 230.4K
- Earning Date
- OCG 04-30-2025
- BIVI 05-13-2025
- Dividend Yield
- OCG N/A
- BIVI N/A
- EPS Growth
- OCG N/A
- BIVI N/A
- EPS
- OCG N/A
- BIVI N/A
- Revenue
- OCG $1,227,855.00
- BIVI N/A
- Revenue This Year
- OCG N/A
- BIVI N/A
- Revenue Next Year
- OCG N/A
- BIVI N/A
- P/E Ratio
- OCG N/A
- BIVI N/A
- Revenue Growth
- OCG N/A
- BIVI N/A
- 52 Week Low
- OCG $0.91
- BIVI $0.80
- 52 Week High
- OCG $3.45
- BIVI $7.50
- Technical
- Relative Strength Index (RSI)
- OCG 78.49
- BIVI 37.09
- Support Level
- OCG $1.25
- BIVI $0.99
- Resistance Level
- OCG $3.31
- BIVI $1.10
- Average True Range (ATR)
- OCG 0.31
- BIVI 0.10
- MACD
- OCG 0.19
- BIVI 0.01
- Stochastic Oscillator
- OCG 79.30
- BIVI 34.07
About OCG Oriental Culture Holding LTD
Oriental Culture Holding Ltd is an online provider of collectibles and artwork e-commerce services. The company also offers online and offline integrated marketing, storage, and technical maintenance service to customers in China and Hong Kong. It operates through one segment namely, e-commerce of artwork trading. It generates revenue through listing service fees, transaction fees, and other revenues collected from traders.
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.